CV340B’s Northeast Regional Advocacy Plans ‘340B in the Northeast’ Webinar for May 25th, 2021

CV340B’s Northeast Regional Advocacy Group is hosting a webinar titled ‘340B in the Northeast’ scheduled for 11:00am- 12:00pm on Tuesday May 25th, 2021. Webinar will include a brief history of the 340B Drug Pricing Program, current threats to the program, a panel of Northeastern providers and a discussion on advocacy. The panel will discuss how…

HRSA Determines Six Manufacturers’ Contract Pharmacy Policies Violate 340B Statute

Yesterday, HRSA Acting Administrator Diana Espinosa sent letters to Eli Lilly, AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics making clear to the manufacturers that their restrictions on access to 340B pricing at contract pharmacies “have resulted in overcharges and are in direct violation of the 340B statute.”  As a result, HRSA is requiring the six manufacturers…

340B providers filed an amicus brief in opposition to AstraZeneca’s motion to invalidate Advisory Opinion.

On May 4, 2021, 340B safety-net providers and their trade associations filed a brief in the case brought by AstraZeneca Pharmaceuticals LP (AstraZeneca) against the U.S. Department of Health and Human Services (HHS) seeking to invalidate the former HHS General Counsel’s 2020 Advisory Opinion on contract pharmacy arrangements.  The brief was filed jointly with the…

Arkansas Passes Comprehensive 340B Anti-Discriminatory Reimbursement Bill, Protects Covered Entities Rights to Use Contract Pharmacies

Last week, Arkansas passed legislation (HB 1881) intended to address 340B discriminatory pricing practices by third party payers and pharmacy benefit managers (PBMs).  The law also addresses drug manufacturers denying access to 340B pricing at contract pharmacies.  The bill has been sent to Governor Asa Hutchinson for his signature.   The “340B Drug Pricing Nondiscrimination…